Cytokinetics Presents New Data at CMR 2024 From FOREST-HCM, the Open Label Extension Clinical Trial of AficamtenGlobeNewsWire • 01/25/24
Cytokinetics Steps Up As Prime Target After Aficamten's HCM Triumph (Rating Upgrade)Seeking Alpha • 01/12/24
Cytokinetics Rockets 14% As Novartis Reportedly Nears A Buyout DealInvestors Business Daily • 01/08/24
Cytokinetics Stock Skyrockets on Positive Results from Study of Its Heart DrugInvestopedia • 12/27/23
Cytokinetics stock rockets toward a 19-year high after positive trial data on heart disease treatmentMarket Watch • 12/27/23
Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic CardiomyopathyGlobeNewsWire • 12/27/23
Cytokinetics to Host Investor Call on December 27 to Discuss the Topline Results from SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Obstructive Hypertrophic CardiomyopathyGlobeNewsWire • 12/26/23